ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Interest Expense
Cost of servicing the company's debt during the period.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense remains negative
Q1 FY2026 interest expense was $1.38M, compared with $0 a year earlier. Trailing-twelve-month interest expense was $2.71M. Over 3 fiscal years it compounded at +208.9% a year.
Context
- Interest expense amounted to 6.5% of revenue in FY2025, up 6.5 pp from a year earlier.
- Interest expense increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly interest expense holds near $1.38M or moves back toward the trailing-twelve-month quarterly average of $677K.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 2.39M USD
- Year-over-year change
- —
- 4-year CAGR
- +25.2%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.39M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 81K | -91.7% |
| FY2021 | 2021-12-31 | 973K | — |
Interest Expense vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
- Interest expense amounts to 6.7% of revenue for CLPT, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $42.1M USD | +23.8% | -4.7% | 4.9% | |
| LTM Mar 2026 | $18.65M USD | -37.0% | +138.6% | 2.3% | |
| LTM Mar 2026 | $11.72M USD | -50.0% | +15.5% | 5.0% | |
| LTM Mar 2026 | $7.2M USD | -35.7% | -26.3% | 1.0% | |
| LTM Mar 2026 | CA$5.69M CAD | -24.9% | +8.4% | 0.6% | |
| LTM Mar 2026 | $4.85M USD | +7.6% | — | — | |
| LTM Mar 2026 | $2.71M USD | — | +208.9% | 6.7% | |
| LTM Mar 2026 | $2.56M USD | -20.6% | +23.3% | 1.2% | |
| LTM Mar 2026 | $1.9M USD | +248.3% | -43.1% | 0.9% | |
| LTM Mar 2026 | $24K USD | -97.2% | -81.8% | 0.0% | |
| Peer median (excluding CLPT) | — | -24.9% | +1.9% | 1.1% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 16.3M | 20.55M | 23.96M | 31.39M | 36.97M |
| Cost of Revenue | 5.18M | 7.02M | 10.34M | 12.27M | 14.28M |
| Gross Profit | 11.12M | 13.53M | 13.61M | 19.12M | 22.69M |
| Gross Margin | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Research & Development | 9.28M | 10.89M | 11.71M | 12.39M | 13.9M |
| Selling, General & Admin | 15.22M | 18.97M | 24.35M | 26.48M | 32.96M |
| Operating Expenses | 24.5M | 29.86M | 36.06M | 38.87M | 46.86M |
| Depreciation & Amortization | 692K | 777K | 1.46M | 1.9M | 2.24M |
| EBITDA | (12.75M) | (15.58M) | (20.63M) | (17.01M) | (20.86M) |
| EBITDA Margin | -78.2% | -75.8% | -86.1% | -54.2% | -56.4% |
| Operating Income | (13.37M) | (16.33M) | (22.45M) | (19.75M) | (24.16M) |
| Operating Margin | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Interest Income | 0 | 0 | 386K | 872K | 1.21M |
| Interest Expense | 973K | 81K | 0 | 0 | 2.39M |
| Other Income / Expenses | (1.04M) | (103K) | 357K | 832K | (1.32M) |
| Income Before Tax | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.49M) |
| Pre-Tax Margin | -88.4% | -80.0% | -92.2% | -60.3% | -68.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 55K |
| Net Income | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.54M) |
| Net Margin | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| EPS (Basic) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| EPS (Diluted) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| Weighted Avg Shares | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
| Weighted Avg Shares (Diluted) | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.